Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

Mark J. McKeage,Dusan Kotasek,Ben Markman,Manuel Hidalgo,Michael Millward,Michael B. Jameson,D. Harris,Robert Joseph Stagg,Ann M. Kapoun,Lu Xu,Brett Hughes

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

2018

Mark J. McKeage
Dusan Kotasek
Ben Markman
Manuel Hidalgo
Michael Millward
Michael B. Jameson
D. Harris
Robert Joseph Stagg
Ann M. Kapoun
Lu Xu
Brett Hughes

Background Delta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance of chemotherapy-resistant cancer stem cells and tumor vasculature.

Keywords:

Carboplatin
Pharmacology
Pemetrexed
Demcizumab
Medicine
Cancer research
Cancer stem cell
Tumor vasculature
Text mining
Regimen
Lung cancer
Internal medicine
Pharmacodynamics
Oncology
Chemotherapy
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations